After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, URGN falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of UroGen Pharma Ltd is $195.50M. A total of 2.9 million shares were traded on the day, compared to an average of 1.14M shares.
In the most recent transaction, Schoenberg Mark sold 4,551 shares of URGN for 11.14 per share on Jan 31 ’25. After the transaction, the Chief Medical Officer now owns 145,666 company shares. In a previous transaction on Jan 31 ’25, Smith Jason Drew sold 7,379 shares at 11.14 per share. URGN shares that General Counsel owns now total 26,468.
Among the insiders who sold shares, Schoenberg Mark disposed of 859 shares on Sep 09 ’24 at a per-share price of $13.08. This resulted in the Chief Medical Officer holding 145,091 shares of URGN after the transaction. In another insider transaction, Smith Jason Drew sold 1,521 shares at $13.08 per share on Sep 09 ’24. Company shares held by the General Counsel now total 25,226.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, URGN has a high of $20.70 and a low of $3.42.
As of this writing, URGN has an earnings estimate of -$0.81 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.6 per share and a lower estimate of -$0.95.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. URGN’s latest balance sheet shows that the firm has $89.14M in Cash & Short Term Investments as of fiscal 2021. There were $398.00k in debt and $22.38M in liabilities at the time. Its Book Value Per Share was -$1.01, while its Total Shareholder’s Equity was $8.41M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for URGN is Buy with a score of 4.50.
